Inhibition of B7-1 (CD80) by RhuDex® reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions
Received 22 December 2013
Accepted for publication 25 February 2014
Published 12 May 2014 Volume 2014:8 Pages 447—457
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Andreas O Doesch,1,* Li Zhao,1,* Christian A Gleissner,1 Mohammadreza Akhavanpoor,1 David Rohde,1 Deniz Okuyucu,1 Maani Hakimi,2 Thomas J Dengler,3 Hugo A Katus,1 Christian Erbel1
1Department of Cardiology, 2Department of Vascular Surgery, University of Heidelberg, Germany; 3Department of Cardiology, SLK Hospital Heilbronn, Bad Friedrichshall, Germany
*These authors contributed equally to this article
Background: Atherosclerosis is based on a chronic inflammatory process including the innate and adaptive immune response. Costimulatory molecules and their receptors provide decisive signals for antigen-specific cell activation. The contribution of B7-related pathways to atherosclerosis has hardly been explored.
Methods: In the present study, we investigated the contribution of B7-1 to inflammation and tissue injury in the human plaque microenvironment in order to identify possible target structures of future therapeutic agents ex vivo and in vitro.
Results: Carotid artery plaque stimulation with lipopolysaccharides (LPS) could be significantly inhibited by RhuDex®, a specific inhibitor of the costimulatory molecule B7-1 ex vivo (P<0.001). Coculture of antigen-presenting cells with T-cells demonstrated that the inhibitory effects of RhuDex® derived from reduced T-cell activation. In addition, incubation of monocytes/macrophages with LPS and RhuDex® resulted in an inhibitory negative feedback on antigen-presenting cells. Signaling pathways affected by RhuDex® seem to be nuclear transcription factor kappa B, activator protein-1, and extracellular signal-regulated kinase 1/2.
Conclusion: The present data support B7-1 alone as an important costimulatory molecule in the context of LPS-mediated inflammation in atherosclerotic lesions. Due to its marked inhibitory effects, RhuDex® may be a useful therapy to modulate the inflammatory milieu in atherosclerosis.
Keywords: B7, CD86, costimulation, atherosclerosis
The development, progression, and vulnerability of an atherosclerotic lesion results from a chronic inflammatory process.1–3 Various immune cells such as T-cells, macrophages, and dendritic cells (DCs), with their important cytokines tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), interleukin (IL)-6, and chemokines such as monocyte chemoattractant protein-1 (MCP-1), are primarily involved in this process.2,4 Following the uptake of autoantigens such as oxidized low density lipoprotein, antigen-presenting cells (APCs) become activated and present the processed antigen predominantly to naïve T-cells.5
The costimulatory molecules B7-1/B7-2 (CD80/CD86) on the surface of APCs bind to CD28/cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) on T-cells. Interaction between B7-1/B7-2 and the stimulatory receptor CD28 on T-cells is crucial for T-cell activation and proliferation, whereas binding to CTLA-4 resulted in a T-cell activation downregulation.6 It is not clear whether B7-1 and B7-2 effects differ significantly from each other. B7-1, which is not constitutively expressed on the surface of APCs, is inducible by cell activation. By contrast, B7-2 expression is found on most unstimulated APCs but is further upregulated after stimulation.7,8 Recent publications indicated that B7-1 had an inhibitory role in the regulation of T-cell activation while B7-2 showed stimulatory effects.9–11 In contrast, other studies suggested that B7-1 and B7-2 could provide similar costimulatory signals to T-cell activation, cytokine production, and generation of cytotoxic T lymphocyte.12
The contribution of B7-1/B7-2:CD28/CTLA-4 pathways to atherosclerosis remains controversial.4,13–15 In mice, the data for B7-1/B7-2:CD28/CTLA-4 in the context of atherosclerosis showed both a proinflammatory as well as an anti-inflammatory effect.13–15 In human lesions, de Boer et al demonstrated that the expression of B7-1 and B7-2 was most intense on macrophages in the superficial layers of the intima.16 We previously reported that B7-2 was expressed markedly higher in carotid artery plaques of patients with ischemic symptoms such as stroke or transient ischemic attack (TIA) compared to asymptomatic patients.4
The current study intended to further investigate the role of B7-1 in the context of a lipopolysaccharide (LPS)-dependent immune response in atherosclerotic lesions by blocking B7-1 with RhuDex®, a small molecule that specifically binds to B7-1.17
Materials and methods
Ex vivo experiments
Fresh carotid artery plaques were obtained from 12 patients undergoing endarterectomy: six had ischemic symptoms while six were asymptomatic. The current study only used lipid-rich or complicated lesions. Plaque morphology was categorized on the basis of the American Heart Association classification.18 A lipid-rich lesion was defined as a confluent extracellular lipid core formed with adaptive intimal thickening (type IV lesion, n=6). The presence of a surface defect, thrombosis, and hematoma constituted complicated plaques (type VI lesion, n=6). Approval for this study was given by the Institutional Review Board of the University of Heidelberg, Germany, and appropriate informed consent was obtained from all patients. Specimens were cut into small pieces (3 mm) and randomly planted into wells of a 48-well plate with Roswell Park Memorial Institute (RPMI) medium (with 10% fetal calf serum, 100 U/mL penicillin G, and 100 g/mL streptomycin). Tissues were stimulated with 1 μg/mL of LPS (from Escherichia coli 055:B5; Sigma-Aldrich, St Louis, MO, USA), and partly treated with 3 μg/mL RhuDex® (Medigene AG, Planegg/Martinsried, Germany) for 3 hours and 8 hours. Unstimulated cultured plaque pieces served as controls. Cultured tissues were maintained at 37°C in humidified air containing 5% CO2. After stimulation, plaque tissues were shock-frozen in liquid nitrogen for quantitative polymerase chain reaction analysis (qPCR) or lysed for western blotting. The supernatant was collected and stored at −20°C for enzyme-linked immunosorbent assay (ELISA) protein analysis. The study was conducted according to good clinical practice and in compliance with the 2008 Declaration of Helsinki.
In vitro experiments
Peripheral blood mononuclear cells (PBMCs) were derived from healthy donors by density gradient centrifugation using Ficolite-H (Linaris, Wertheim, Germany). Monocytes were isolated by adherence method as described previously.19 Briefly, isolated PBMCs were planted in a 6-well plate (Corning Incorporated, Corning, NY, USA) at a density of 20×106/cm2 for 20~30 minutes. Afterwards, nonattached cells were removed by vigorously washing three times with 1× phosphate buffered saline. Adherent monocytes were recovered by mechanical detachment. For macrophage differentiation, monocytes were seeded in a 24-well plate in macrophage serum-free medium (Gibco macrophage-SFM; Life Technologies, Carlsbad, CA, USA) with 1% Nutridoma (Roche, Basel Switzerland) and 100 ng/mL recombinant human macrophage-colony stimulating factor (PeproTech, Rocky Hill, NJ, USA) for 6 days. Medium was changed every 2 days with the addition of macrophage-colony stimulating factor. CD4+ T-cells were isolated from PBMCs using a Dynabeads Flow Comp™ Human CD4+ kit (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s protocol. For coculture, T-cells and monocytes were derived from the same donor.
Monocytes and monocyte-derived macrophages were stimulated with 1 μg/mL LPS and/or 3 μg/mL RhuDex® alone or in combination for indicated periods. Unstimulated cells served as controls. Cells were harvested after incubation for RNA isolation and qPCR analysis. In addition, the supernatant were stored at −20°C until use.
Electrophoretic mobility shift assay
Nuclear proteins from monocytes were prepared in nuclear extraction buffer as described previously.20 Briefly, protein concentration was measured by Multiskan® Spectrum (Thermo Fisher Scientific, Waltham, MA, USA). Consensus oligonucleotides (nuclear factor-kappa B [NF-κB] and activator protein-1 [AP-1]; Promega Corporation, Fitchburg, WI, USA) were end-labeled with [γ-32P] ATP 3,000 Ci/mmol (Dupont NEN Research Products, Boston, MA, USA). Nuclear proteins (5 μg) were incubated with a labeled oligonucleotide probe in binding buffer at room temperature for 30 minutes, and then separated in 5% nondenaturating polyacrylamide gel (Acrylamide/Bis-acrylamide at a ratio of 29:1, 50 mM Tris-HCl, 380 mM glycine, 2 mM ethylenediaminetetraacetic acid [EDTA], 2.5% glycerol). The dried gel was exposed to autoradiography film at −80°C with enhancer foils.
Supernatants from plaques were analyzed with ELISA kits (Roche and eBioscience, San Diego, CA, USA) as described by the manufacturer’s specifications.
Carotid plaques were cultured as described above. After indicated periods of culture, plaque tissues were smashed and lysated in lysis buffer containing 1% sodium dodecyl sulfate, 1 mM EDTA/ethylene glycol tetraacetic acid, 10 μL/mL phosphatase inhibitor cocktail 2/3 (Sigma-Aldrich), and one protease inhibitor cocktail tablet (Roche). The supernatant was recovered by centrifugation at 14,000 rpm at 4°C for 5 minutes. Removal of impurities from the supernatant was implemented with 0.65 μm and 0.1 μm centrifugal filter devices (Millipore Corporation, Billerica, MA, USA). The protein concentration was determined using a Bio-Rad Protein Assay kit (Hercules, CA, USA). A total of 40 μg of each lysate was run on a 4%~12% Bis-Tris gel (Life Technologies), followed by protein transfer to a polyvinylidene fluoride transfer membrane (GE Healthcare Europe GmbH, Freiburg, Germany) using an XCell II™ Blot Module (Life Technologies) according to the manufacturer’s instructions. The membrane was incubated with primary antibodies (for phosphorylated extracellular signal-regulated kinase 1/2 [ERK1/2], phosphorylated I kappa B [IκB], glyceraldehyde 3-phosphate dehydrogenase from Cell Signaling Technology [Danvers, MA, USA] and Santa Cruz [Dallas, TX, USA]) followed by secondary antibody conjugated with horseradish peroxidase (Cell Signaling Technology and Santa Cruz). Protein bands were detected by ECL Western Blotting Substrate (Pierce, Rockford, IL, USA) followed by exposure to X-ray film.
RNA isolation, complementary DNA synthesis, and qPCR
Total cellular RNA was isolated from carotid plaques and immune cells with RNeasy mini kit (QIAGEN, Venlo, the Netherlands) as described previously.20 Complementary DNA (cDNA) was generated using the First Strand cDNA Synthesis kit (Thermo Fisher Scientific) for reverse transcription according to the manufacturer’s instructions. qPCR was performed using the Light Cycler System (Roche) with SYBR Green (LONZA, Basel, Switzerland), Master Mix (Thermo Fisher Scientific) and primers in a final volume of 20 μL. Primer sequences are given in Table 1. Data were analyzed with the relative expression method (the difference in threshold cycle between the target gene and beta-actin as a control).
Data analysis was performed using Prism software (Graphpad, La Jolla, CA, USA). For comparison of two groups, the nonparametric Mann–Whitney U test was used; for comparison of three or more groups, ANOVA was done with post hoc Tukey’s testing. A level of P<0.05 was considered statistically significant.
Inhibitory role of RhuDex® on LPS-induced activation of the inflammatory milieu in atherosclerotic lesions
Stimulation of plaque tissue with LPS resulted in significantly higher protein levels of TNF-α after 3 hours and 8 hours and IFN-γ after 8 hours in the supernatant (Figure 1A–D). Similarly, protein levels of the chemokine MCP-1, primarily expressed by APCs, in the supernatant of LPS-stimulated plaques were also significantly upregulated at indicated time points (Figure 1E and F). Plaque pieces incubated with LPS in addition to RhuDex® showed a total inhibition of LPS-induced upregulation of TNF-α expression after 3 hours and 8 hours and IFN-γ after 8 hours (Figure 1A–D). Serum protein levels of MCP-1 showed no significant difference between LPS and LPS in addition to RhuDex® after both time points (Figure 1E and F).
To evaluate whether the downregulation of TNF-α and IFN-γ is triggered by an upregulation of anti-inflammatory cytokine IL-10, we measured the levels of the molecule in the supernatant. Interestingly, the study demonstrated that RhuDex® significantly inhibited LPS-induced upregulation of IL-10 in the supernatant of plaques incubated with LPS and RhuDex® after 3 hours and no difference after 8 hours (Figure 1G and H).
qPCR results of cultured plaques underlined ELISA analysis showing an inhibitory effect of RhuDex® on LPS-induced inflammatory response in atherosclerotic lesions. Messenger RNA (mRNA) expression levels of cytokine TNFα were highly upregulated after 3 hours and 8 hours of LPS stimulation (Table 2), whereas IFNγ showed only a significant increase after 8 hours (Table 2). Besides molecules predominantly expressed by T-cells, LPS stimulation of plaque tissues displayed a significant increase of intercellular adhesion molecule-1 (ICAM1), involved in atherogenesis, and prothrombotic molecule tissue factor (TF ) after 3 hours and 8 hours (Table 2). LPS in addition to RhuDex® resulted in a significant inhibition of mRNA level upregulation of TNFα, IFNγ, ICAM1, and TF after 3 hours and 8 hours compared to LPS alone (Table 2).
Notably, no difference was found for RhuDex® alone versus unstimulated plaque pieces according to the measured molecules, respectively.
Effects of RhuDex® on LPS-induced cell activation in atherosclerotic lesions are independent of patients’ symptoms and plaque morphology
In order to analyze whether plaque pieces from patients with or without ischemic symptoms (stroke or TIA) or the plaque morphology (complicated lesion versus lipid-rich lesion) influenced the inhibitory functions of RhuDex®, we grouped the plaque pieces according to symptomatic patients and type of plaque. The study demonstrated that neither the symptoms nor plaque morphology had an effect on the inhibitory function of RhuDex® on LPS-induced plaque activation (plaque morphology, Table 3; with or without ischemic symptoms, data not shown).
Effects of RhuDex® on LPS-induced T-cell activation in vitro
To further investigate the specific inhibitory effects of B7-1 by RhuDex®, we stimulated monocytes cocultured with T-cells with LPS. qPCR results of cultured plaques displayed that RhuDex® had an inhibitory effect on LPS-induced upregulation of proinflammatory cytokines TNFα and IFNγ, both expressed by T-cells, and chemokine CCL2 (Figure 2A–E). RhuDex® had no effect on LPS-induced upregulation of IL6 and IL10 (Figure 2C and D).
RhuDex® inhibits the LPS-induced expression of cytokines and chemokines in different inflammatory cells in vitro
Since RhuDex® inhibited not only the expression of T-cell activation dependent molecules such as TNFα and IFNγ, but also of ICAM1 and TF, we further studied specific effects of this drug on monocytes and macrophages in vitro.
To further evaluate the origin of molecular expression, we stimulated human blood-derived monocytes and macrophages with LPS (in addition to RhuDex®) for 3 hours. Incubation of monocytes with LPS and RhuDex® resulted in significant lower mRNA expression levels of cytokines TNFα, IFNγ, IL6, and IL10 as well as the chemokine CCL2 (MCP-1) compared to LPS alone (Figure 3A–E).
Monocyte-derived macrophages were also stimulated with LPS (in addition to RhuDex®) for 3 hours. qPCR analysis demonstrated that coincubation of macrophages with LPS and RhuDex® resulted in reduced expression of TNFα, IFNγ, and IL10 than LPS alone (data not shown). No inhibitory effect was observed on CCL2 (MCP-1) and IL6 expression (data not shown).
RhuDex® modulates expression of cytokines and chemokines by inhibiting NF-κB-, AP-1-, and ERK1/2-related signaling pathways
In order to further analyze how the effect of RhuDex® is mediated, we investigated the signal cascade NF-κB, ERK1/2, and signal transducer and activator of transcription (STAT)4, known to be involved in the expression of IFN-γ, TNF-α, IL-6, IL-10, and MCP-1 ex vivo. Using electrophoretic mobility shift assay of nuclear extracts, the study revealed a significant decrease in the activity of NF-κB and AP-1 in the LPS and RhuDex® group compared to the LPS group after 3 hours of stimulation ex vivo and in vitro (ex vivo Figure 4A and B; in vitro not shown). Furthermore, results of Western blot further demonstrated a significant reduction of phosphorylated IκB, whereas IκB was significantly increased (Figure 4C). In addition, activation of ERK1/2 was also detected and showed that phosphorylated ERK1/2 in relation to total ERK1/2 was markedly reduced by RhuDex® in addition to LPS compared to LPS alone. This resulted in an inactivation of AP-1 (Figure 4). Notably, no difference was found for STAT4 between the groups (data not shown).
RhuDex® as a specific B7-1 inhibitor is able to inhibit LPS-mediated plaque tissue inflammation and cytokine (TNF-α, IFN-γ, IL-6), chemokine (MCP-1), adhesion molecule (ICAM1), and prothrombotic molecule (TF) expression in atherosclerotic lesions. These results are found to be independent of the lesion type (stable and vulnerable) and symptoms of patients (stroke and TIA versus no symptoms). RhuDex® not only inhibited T-cell activation but also negatively influenced APC activation. The effects of RhuDex® are due to a reduced expression of atherogenic promoters by downregulating phosphorylation of ERK1/2 and transcription factors NF-κB/AP-1.
In order to evaluate the impact of the specific B7-1 inhibitor RhuDex® on the lesional cellular compound, we evaluated LPS as an adequate stimulator. LPS is a potent toll-like receptor (TLR)4 signaling activator and already described to activate the inflammatory compound in human atherosclerotic lesions ex vivo.22 The pathophysiologic aspect of TLR4 in atherogenesis relates to its additional ligands, known autoantigens in atherogenesis such as heat shock protein 60 from Chlamydia pneumoniae or oxidized low density lipoprotein. In addition, TLR expression is upregulated in macrophages and endothelial cells in human atherosclerotic plaques, and their signaling has implications for lesion development, foam cell formation, inflammation, matrix degradation, and ischemia-reperfusion.23–25
Moreover, B7-1 is constantly expressed on different atherogenic cell types such as monocytes and macrophages, and LPS is known to upregulate this costimulatory molecule.26–28 By inducing APCs due to LPS, these cells are capable of activating T-cells. This step is major histocompatibility complex-unrestricted but is strongly dependent on interactions of CD28 and/or CTLA-4 on T-cells and their ligands B7-1/B7-2 on APCs.29 The current study is in line with previous results showing that LPS activation induced an upregulation of the expression of various inflammatory molecules in cultured plaques as well as in monocytes and macrophages, which are known to be primarily involved in atherogenesis.30–34 Thus, it can be concluded that LPS represents a good candidate to investigate the role of B7-1 on lesional inflammation.
Various cytokines and chemokines are involved in atherogenesis. TNF-α, IFN-γ, and IL-6 are major proinflammatory cytokines, known to promote atherosclerosis and plaque instability, whereas anti-inflammatory cytokine IL-10 is known to inhibit plaque development and progression.30–33,35–37 ICAM1, as a major adhesion molecule, and MCP-1, as a potent chemoattractant, also display proatherogenic functions.38,39 TF, one of the prothrombotic molecules, is known to be primarily involved in the initiation of a thrombus formation.34 Our study demonstrates that RhuDex® has potent inhibitory effects on the activation of the inflammatory milieu in atherosclerotic lesions by inhibiting the secretion of proinflammatory mediators induced by LPS stimulation both ex vivo and in vitro. Interestingly, the effects of RhuDex® were not restricted to T-cell-derived molecular expression but also other cell types such as APCs. Thus, it can be suggested that B7-1 is involved in the inflammatory milieu of an atherosclerotic lesion.
The mechanism by which RhuDex® acts as a specific B7-1 inhibitor is capable of inhibiting APC activation induced by LPS. It is known that in vitro regulatory T-cells specifically downregulate the expression of B7-1/B7-2 on DCs in both a CTLA-4- and lymphocyte function-associated antigen-1-dependent manner.40 This B7-1/B7-2 downmodulating effect was still present, even in the presence of the strong DC-dependent stimuli of LPS.40 This indicates that blockade of B7-1/B7-2 resulted in a negative feedback in APCs. However, it remains unknown whether the grade of APC activation can be also inhibited by the negative feedback. Our study clearly demonstrated that blockade of B7-1 by RhuDex® inhibited the upregulation of various molecules expressed by APCs, independently of interaction with T-cells. Thus, blockade of the B7-1 receptor by RhuDex® inhibited LPS-induced activation of APCs, most likely by a B7-1 receptor-dependent negative feedback in APCs. Additional studies are needed to further investigate the possible negative feedback.
To further evaluate the finding of a general inhibition of the LPS-induced cellular activation by RhuDex®, we focused on IL-10. IL-10 is an anti-inflammatory cytokine produced by T-cells, macrophages, monocytes, and DCs.36,37 A potent effect of IL-10 is to inhibit the production of mediators, including TNF-α, IFN-γ, IL-6, and MCP-1.41 It is further known that IL-10 gene expression is regulated by many transcription factors involving NF-κB, STAT1/3, AP-1, CCAAT/enhancer binding protein (C/EBP)β and C/EBPδ.41–44 Interestingly, the study revealed that upregulation of IL-10 by LPS was also inhibited by RhuDex®. Thus, IL-10 is not responsible for the effects of RhuDex® on cytokine expression. The underlying signaling pathway is at least in part mediated by NF-κB/AP-1. In conclusion, it can be suggested that the RhuDex®-dependent negatively-influenced cytokine expression seems to be based on a general inhibition of the induction of cellular activation induced by LPS rather than mediated by anti-inflammatory cytokine IL-10 in atherosclerotic lesions.
In evaluating the inhibitory effect on cellular activation and molecular expression by RhuDex®, we used electrophoretic mobility shift assay and western blot to investigate possible signaling cascades. It can be speculated that activation of the lesional cellular compound via LPS further degrades IκB and mitogen-activated protein kinases, thereby inducing NF-κB and mitogen-activated protein kinase-dependent gene transcription as shown in recent publications.23,45,46 LPS-induced TNF-α gene expression is dependent on the activation of ERK1/2, whereas MCP-1 is regulated by NF-κB and ERK1/2-dependent pathways.47 An early activation of AP-1 and NF-κB further leads to a significant increase in IL-6 gene expression, and IFN-γ production is regulated by a variety of transcription factors.48,49 Subsequently, this may lead to enhanced inflammation by triggering the induction of additional adhesion molecules, cytokines, and growth factors. The current findings demonstrate that the inhibitory effect of RhuDex® on cellular activation and expression of various molecules are likely due to the inhibition of NF-κB and ERK1/2 pathways.
The contribution of B7-1 and B7-2 costimulation to immune responses in atherosclerotic lesions remains controversial and illustrates the complexity of these pathways. Buono et al showed that cholesterol diet-fed B7-1–/–/B7-2–/– Ldlr–/– mice had significantly reduced atherosclerotic lesion development.14 The B7-1–/–/B7-2–/– Ldlr–/– knockout resulted in less IFN-γ production of CD4+ T-cells in response to the TLR4 ligand heat shock protein 60 in vitro.14 In contrast, Ait-Oufella et al showed that irradiated bone marrow chimeric Ldlr–/– mice reconstituted with B7-1–/–/B7-2–/–, CD28–/– resulted in increased atherosclerotic lesion development. These changes were based on an impaired regulatory T-cell development and an enhanced proatherogenic effector T-cell response.15 However, these findings are derived from mouse studies while only few studies examined the presence of B7-1 and B7-2 in human atherogenesis. de Boer et al demonstrated that the expression of B7-1 and B7-2 was highest on macrophages in the superficial layers of the intima from human arterial segments.16 We previously found that B7-2 was expressed markedly higher in carotid artery plaques of patients with ischemic symptoms such as stroke or TIA.4 The current study clearly demonstrates that B7-1 seems to be a major proinflammatory component in the cascade initiating an innate and adaptive immune response inside atherosclerotic lesions. Thus, B7-1 seems to be primarily a proatherogenic mediator in the inflammatory process in human atherosclerotic lesions and may be an interesting target of future therapeutic agents in vivo.
It was not the intention of the study to compare the effects of RhuDex® in atherosclerotic lesions of symptomatic and asymptomatic patients or on plaque morphology. However, the results of the study show that the stimulatory capacity of LPS is comparable between both groups (data not shown). In addition, the inhibitory functions of RhuDex® showed no difference according to patients with or without ischemic symptoms or plaque morphology. Thus, the role of RhuDex® on the inflammatory response to TLR4 ligand LPS is comparable between atherosclerotic lesions of patients with ischemic symptoms and plaque morphology.
In conclusion, RhuDex® as a specific B7-1 inhibitor appears to show a universal inhibitory effect on LPS-induced inflammation in atherosclerotic lesions. The finding of a possible B7-1-dependent negative feedback on APCs reflects a promising new field of investigation. Therefore, due to the strong anti-inflammatory effects against TLR4-induced lesional cell activation by LPS, RhuDex® seems to have the potential capability to be a promising anti-inflammatory agent, which provides a novel potential therapeutic prospect of atherosclerosis.
We thank Nadine Wambsganss for excellent technical assistance. This work was supported by a stipend from the German Academic Exchange Service to Li Zhao and by a research grant from Medigene AG to Christian Erbel.
The authors report no conflicts of interest in this work. Andreas O Doesch received a grant from Deutsche Forschungsgemeinschaft and Ruprecht-Karls-Universität Heidelberg within the funding program Open Access Publishing.
Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999; 340(2):115–126.
Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol. 2009;27:165–197.
Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20(5):1262–1275.
Erbel C, Sato K, Meyer FB, et al. Functional profile of activated dendritic cells in unstable atherosclerotic plaque. Basic Res Cardiol. 2007;102(2):123–132.
Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol. 2004;22:361–403.
Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2(2):116–126.
Freeman GJ, Gribben JG, Boussiotis VA, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science. 1993;262(5135):909–911.
Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med. 1994;180(2):631–640.
Boulougouris G, McLeod JD, Patel YI, Ellwood CN, Walker LS, Sansom DM. Positive and negative regulation of human T cell activation mediated by the CTLA-4/CD28 ligand CD80. J Immunol. 1998;161(8):3919–3924.
Inobe M, Aoki N, Linsley PS, et al. The role of the B7-1a molecule, an alternatively spliced form of murine B7-1 (CD80), on T cell activation. J Immunol. 1996;157(2):582–588.
Chai JG, Vendetti S, Amofah E, Dyson J, Lechler R. CD152 ligation by CD80 on T cells is required for the induction of unresponsiveness by costimulation-deficient antigen presentation. J Immunol. 2000;165(6):3037–3042.
Lanier LL, O’Fallon S, Somoza C, et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol. 1995;154(1):97–105.
Gotsman I, Sharpe AH, Lichtman AH. T-cell costimulation and coinhibition in atherosclerosis. Circ Res. 2008;103(11):1220–1231.
Buono C, Pang H, Uchida Y, Libby P, Sharpe AH, Lichtman AH. B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation. 2004;109(16):2009–2015.
Ait-Oufella H, Salomon BL, Potteaux S, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med. 2006;12(2):178–180.
de Boer OJ, Hirsch F, van der Wal AC, van der Loos CM, Das PK, Becker AE. Costimulatory molecules in human atherosclerotic plaques: an indication of antigen specific T lymphocyte activation. Atherosclerosis. 1997;133(2):227–234.
Haanstra KG, Endell J, Estévâo D, Kondova I, Jonker M. Blocking T cell co-stimulation using a CD80 blocking small molecule reduces delayed type hypersensitivity responses in rhesus monkeys. Clin Exp Immunol. 2009;158(1):91–98.
Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol. 2000;20(5):1177–1178.
Gleissner CA, Shaked I, Erbel C, Böckler D, Katus HA, Ley K. CXCL4 downregulates the atheroprotective hemoglobin receptor CD163 in human macrophages. Circ Res. 2010;106(1):203–211.
Erbel C, Chen L, Bea F, et al. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J Immunol. 2009;183(12):8167–8175.
Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke. 2006;37(7):1923–1932.
Niessner A, Shin MS, Pryshchep O, Goronzy JJ, Chaikof EL, Weyand CM. Synergistic proinflammatory effects of the antiviral cytokine interferon-alpha and Toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation. 2007;116(18):2043–2052.
Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42(2):145–151.
Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002;105(10):1158–1161.
Monaco C. The tolls and dangers of atherosclerotic disease. Curr Pharm Biotechnol. 2012;13(1):77–87.
Lim W, Gee K, Mishra S, Kumar A. Regulation of B7.1 costimulatory molecule is mediated by the IFN regulatory factor-7 through the activation of JNK in lipopolysaccharide-stimulated human monocytic cells. J Immunol. 2005;175(9):5690–5700.
Curiel RE, Garcia CS, Rottschafer S, Bosco MC, Espinoza-Delgado I. Enhanced B7-2 gene expression by interferon-gamma in human monocytic cells is controlled through transcriptional and posttranscriptional mechanisms. Blood. 1999;94(5):1782–1789.
Creery WD, Diaz-Mitoma F, Filion L, Kumar A. Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype. Eur J Immunol. 1996;26(6):1273–1277.
Mattern T, Flad HD, Brade L, Rietschel ET, Ulmer AJ. Stimulation of human T lymphocytes by LPS is MHC unrestricted, but strongly dependent on B7 interactions. J Immunol. 1998;160(7):3412–3418.
Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol. 2010;134(1):33–46.
Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003;170(2):191–203.
Zhang X, Niessner A, Nakajima T, et al. Interleukin 12 induces T-cell recruitment into the atherosclerotic plaque. Circ Res. 2006;98(4):524–531.
Harvey EJ, Ramji DP. Interferon-gamma and atherosclerosis: pro- or anti-atherogenic? Cardiovasc Res. 2005;67(1):11–20.
Luyendyk JP, Piper JD, Tencati M, et al. A novel class of antioxidants inhibit LPS induction of tissue factor by selective inhibition of the activation of ASK1 and MAP kinases. Arterioscler Thromb Vasc Biol. 2007;27(8):1857–1863.
Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis. 1996;127(2):263–271.
O’Garra A, Vieira P. T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol. 2007;7(6):425–428.
Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008;226:205–218.
Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998;2(2):275–281.
DeGraba TJ. Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque. Neurology. 1997; 49(5 Suppl 4):S15–S19.
Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A. 2008;105(29):10113–10118.
Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol. 2008;180(9):5771–5777.
Cao S, Zhang X, Edwards JP, Mosser DM. NF-kappaB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J Biol Chem. 2006;281(36):26041–26050.
Zhang X, Edwards JP, Mosser DM. Dynamic and transient remodeling of the macrophage IL-10 promoter during transcription. J Immunol. 2006;177(2):1282–1288.
Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity. 2009;31(4):539–550.
Triantafilou M, Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol. 2002;23(6):301–304.
Dobrovolskaia MA, Vogel SN. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect. 2002;4(9):903–914.
Oberbach A, Schlichting N, Blüher M, et al. Palmitate induced IL-6 and MCP-1 expression in human bladder smooth muscle cells provides a link between diabetes and urinary tract infections. PLoS One. 2010;5(5):e10882.
Kogut MH, Genovese KJ, He H, Kaiser P. Flagellin and lipopolysaccharide up-regulation of IL-6 and CXCLi2 gene expression in chicken heterophils is mediated by ERK1/2-dependent activation of AP-1 and NF-kappaB signaling pathways. Innate Immun. 2008;14(4):213–222.
Nakahira M, Ahn HJ, Park WR, et al. Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol. 2002;168(3):1146–1153.
© 2014 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.